BR112014005864A2 - compostos de beta-lactama para tratar diabetes - Google Patents

compostos de beta-lactama para tratar diabetes

Info

Publication number
BR112014005864A2
BR112014005864A2 BR112014005864A BR112014005864A BR112014005864A2 BR 112014005864 A2 BR112014005864 A2 BR 112014005864A2 BR 112014005864 A BR112014005864 A BR 112014005864A BR 112014005864 A BR112014005864 A BR 112014005864A BR 112014005864 A2 BR112014005864 A2 BR 112014005864A2
Authority
BR
Brazil
Prior art keywords
beta
treat diabetes
lactam compounds
diabetes
lactam
Prior art date
Application number
BR112014005864A
Other languages
English (en)
Inventor
Mor Felix
R Cohen Irun
Original Assignee
Stem Cell Medicine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Medicine Ltd filed Critical Stem Cell Medicine Ltd
Publication of BR112014005864A2 publication Critical patent/BR112014005864A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

resumo são fornecidas composições e métodos compreendendo ampicilina ou sais e derivado destes para o tratamento ou atraso no início de ação de diabetes tipo i.
BR112014005864A 2011-09-21 2012-09-20 compostos de beta-lactama para tratar diabetes BR112014005864A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161537105P 2011-09-21 2011-09-21
PCT/IL2012/050378 WO2013042121A1 (en) 2011-09-21 2012-09-20 Beta-lactam compounds for treating diabetes

Publications (1)

Publication Number Publication Date
BR112014005864A2 true BR112014005864A2 (pt) 2017-03-28

Family

ID=47913973

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005864A BR112014005864A2 (pt) 2011-09-21 2012-09-20 compostos de beta-lactama para tratar diabetes

Country Status (8)

Country Link
US (1) US9474744B2 (pt)
EP (1) EP2758054B1 (pt)
CN (1) CN104023721A (pt)
AU (1) AU2012311050A1 (pt)
BR (1) BR112014005864A2 (pt)
CA (1) CA2850558A1 (pt)
HK (1) HK1201466A1 (pt)
WO (1) WO2013042121A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020210983B2 (en) * 2019-01-23 2024-05-16 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
WO1997021675A1 (en) 1995-12-08 1997-06-19 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US6255467B1 (en) 1997-11-06 2001-07-03 Pathobiotek Diagnostics Inc. Human blood bacterium
LV12403B (lv) 1998-06-10 2000-02-20 Latvijas Organiskās Sintēzes Institūts Citotoksiskie penicilānskābes atvasinājumi
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
AU781218B2 (en) 1999-08-16 2005-05-12 Revaax Pharmaceuticals, Llc Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
AU2003202942A1 (en) 2002-01-17 2003-09-02 R.E.D. Laboratories, N.V./S.A. Methods of treatment of chronic immune disease
US7026472B2 (en) 2002-05-06 2006-04-11 University Of South Florida Methods for preventing and treating cancer using N-thiolated β-lactam compounds and analogs thereof
US7250438B2 (en) 2004-06-08 2007-07-31 Nereus Pharmaceuticals, Inc. Anti-bacterial and anti-cancer spiro beta-lactone/gamma-lactams
ES2357800T3 (es) 2004-10-30 2011-04-29 Universidad Del Pais Vasco-Euskal Herriko Unibersitatea Ciclopéptidos rgd beta-lactámicos que contienen giros gamma.
CA2611577A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
KR100697312B1 (ko) 2005-08-31 2007-03-20 한국생명공학연구원 세프트리악손을 포함하는 ｓｔａｔ3 활성 저해 활성을가지는 조성물
WO2010057647A2 (en) * 2008-11-21 2010-05-27 Universita' Degli Studi Di Milano Methods and compositions for the diagnosis and treatment of diabetes
CN101524517A (zh) 2009-04-28 2009-09-09 李红彬 一种治疗上呼吸道感染的中西复合药物
WO2011047153A1 (en) * 2009-10-15 2011-04-21 President And Fellows Of Harvard College Methods for modulating autoimmunity
WO2012103456A2 (en) 2011-01-27 2012-08-02 Board Of Regents, The University Of Texas System Polycyclic beta lactam derivatives for the treatment of cancer

Also Published As

Publication number Publication date
CA2850558A1 (en) 2013-03-28
CN104023721A (zh) 2014-09-03
HK1201466A1 (en) 2015-09-04
US20140234282A1 (en) 2014-08-21
AU2012311050A1 (en) 2014-03-06
EP2758054A1 (en) 2014-07-30
EP2758054B1 (en) 2017-04-12
WO2013042121A1 (en) 2013-03-28
US9474744B2 (en) 2016-10-25
EP2758054A4 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
EA201300211A1 (ru) N-ацилсульфонамидные промоторы апоптоза
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
EA201690844A1 (ru) Ингибиторы gsk-3
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
EA201201623A1 (ru) Лечение диабета 2 типа
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/43 (2006.01), A61K 35/17 (2015.01), A61K 3